How Omnipod® 5 may deliver on psychosocial outcomes
Maintaining the consistent effort and attention required for successful glycaemic management can take a substantial toll on psychosocial wellbeing among people with diabetes and caregivers.1
Tubeless, waterproof* and discreet, the Omnipod® 5 Automated Insulin Delivery System with SmartAdjustTM technology consists of an on-body Pod communicating directly with a compatible sensor, and puts an end to daily injections.† Omnipod® 5 has demonstrated improved patient-reported outcomes as well as glycaemic control.2-4
† 1 Pod replaces up to 14 injections over 3 days (14 is the average number of injections over 3 days).
Successful management of T1D looks beyond glycaemic control1
When managing T1D, we must also consider the burden of diabetes on patients and caregivers. Multiple factors can contribute to diabetes distress among patients and their families, including fear of hypoglycaemia, concerns around eating and the relentless toll of day-to-day management.1,2 Consideration of these factors when implementing a new therapy is important.2,5
Omnipod® 5 users reported increased diabetes treatment satisfaction vs prior therapy in a pivotal study of adolescents and adults with T1D*2,3
Adults reported reduced diabetes distress compared to prior therapy
Mean diabetes distress scale (T1-DDS) score of 1.48 vs 1.64
Adult users and caregivers felt confident in staying safe from the risk of hypoglycaemia compared to prior therapy
Mean hypoglycaemia confidence survey (HCS) score of 3.59 vs 3.34 and 3.65 vs 3.52, respectively
Adults reported lower stress when eating compared to prior therapy
Eating distress survey (T1-DDS Eating Distress Subscale) score of 1.74 vs. 1.97
Caregivers reported a 38% improvement in sleep quality compared to prior therapy.
Mean PSQI Overall Sleep Quality Subscore of 0.70 vs 1.13, (comparison is relative change)
Caregivers reported improved quality of life and mental well-being compared to prior therapy.2,3
* Compared to prior therapy: 14.3% multiple daily injection (MDI), 85.7% continuous subcutaneous insulin infusion (CSII). Assessed via the Diabetes Treatment Satisfaction Questionnaire (DTSQ).
See the Omnipod® 5 data
As well as delivering improvements in patient-reported outcomes, the Omnipod® 5 System has demonstrated improvements in glycaemic control.3,4
Contact our Medical Affairs or Medical Information teams
At Insulet, our aim is to keep on improving the lives of those living with T1D. With this in mind we aim to generate real-world data to provide further evidence on the efficacy of Pod Therapy. If you want to know more about our current trials and development pipeline do not hesitate to contact our Medical Affairs team at [email protected] or our Medical Information team at [email protected].
Arrange a meeting with an Omnipod® representative
Do you have questions about the Omnipod DASH® System? Our team is on call to provide you with the information you need and help you to determine which of your patients could best benefit from the Omnipod DASH® System.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.